title: Effect of salvianolic acid B and paeonol on blood lipid metabolism and hemorrheology in myocardial ischemia rabbits induced by pituitruin.
abstract: The purpose of this study was to determine the therapeutic effect of salvianolic acid b and paeonol on coronary disease. The ischemia myocardial animal model is induced by administering pituitrin (20 μg·kg(-1)) intravenously via the abdominal vein. A combination of salvianolic acid b and paeonol (CSAP) (5, 10 and 15 mg/kg BW) was administrated to experimental rabbits. Biochemical indices were evaluated during six weeks of intervention. We found that the compound of salvianolic acid b and paeonol (5, 10 and 15 mg/kg BW) can markedly and dose-dependently reduce fibrinogen and malonaldehyde levels, increase the HDL level, improve blood viscosity and plasma viscosity in rabbits. In addition, the medicine can still reduce the ratio of NO/ET and the contents of lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) in a dose-dependent manner. This study demonstrates that compound of salvianolic acid b and paeonol (5, 10 and 15 mg/kg BW) can improve the blood hemorrheology, decrease oxidative injury and repair the function of blood vessel endothelium, and subsequently prevent the development of Coronary disease.
authors.affiliation: Institute of Materia Medica, School of pharmacy; Fourth Military Medical University, Xi'an, Shaanxi, 7l0032, China; E-Mails: yanqian379@163.com (Q.Y.); xieyanh@fmmu.edu.cn (Y.X.); wangjp@fmmu.edu.cn (J.W.); 561641505@qq.com (H.L.); yunyaorao@sina.com (X.Z.).
authors.forename: Qian
authors.initials: Q
authors.lastname: Yang
authors.forename: Siwang
authors.initials: S
authors.lastname: Wang
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Xie
authors.forename: Jianbo
authors.initials: J
authors.lastname: Wang
authors.forename: Hua
authors.initials: H
authors.lastname: Li
authors.forename: Xuanxuan
authors.initials: X
authors.lastname: Zhou
authors.forename: Wenbo
authors.initials: W
authors.lastname: Liu
mesh_terms: D000098:Acetophenones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000475:Alkenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D005340:Fibrinogen / Q000378:metabolism; D018056:Hemorheology / Q000187:drug effects*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects*; D008075:Lipoproteins, HDL / Q000097:blood; D008315:Malondialdehyde / Q000097:blood; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D009569:Nitric Oxide / Q000097:blood; D010909:Pituitary Hormones, Posterior / Q000633:toxicity; D059808:Polyphenols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits
chemical_list: D000098:Acetophenones; D000475:Alkenes; D008075:Lipoproteins, HDL; D010909:Pituitary Hormones, Posterior; D059808:Polyphenols; C568740:salvianolic acid; D009569:Nitric Oxide; C013638:paeonol; D008315:Malondialdehyde; D005340:Fibrinogen; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase